These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 31746601)
1. Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. Yang M; Tao B; Chen C; Jia W; Sun S; Zhang T; Wang X J Chem Inf Model; 2019 Dec; 59(12):5002-5012. PubMed ID: 31746601 [TBL] [Abstract][Full Text] [Related]
2. Computer-aided discovery of aminopyridines as novel JAK2 inhibitors. Zhao C; Yang SH; Khadka DB; Jin Y; Lee KT; Cho WJ Bioorg Med Chem; 2015 Mar; 23(5):985-95. PubMed ID: 25650310 [TBL] [Abstract][Full Text] [Related]
3. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284 [TBL] [Abstract][Full Text] [Related]
5. Development of machine learning models based on molecular fingerprints for selection of small molecule inhibitors against JAK2 protein. Belenahalli Shekarappa S; Kandagalla S; Lee J J Comput Chem; 2023 Jun; 44(16):1493-1504. PubMed ID: 36929511 [TBL] [Abstract][Full Text] [Related]
6. Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach. Jasuja H; Chadha N; Kaur M; Silakari O Mol Divers; 2014 May; 18(2):253-67. PubMed ID: 24415188 [TBL] [Abstract][Full Text] [Related]
7. Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. Xu P; Shen P; Wang H; Qin L; Ren J; Sun Q; Ge R; Bian J; Zhong Y; Li Z; Wang J; Qiu Z Eur J Med Chem; 2021 Jun; 218():113394. PubMed ID: 33813153 [TBL] [Abstract][Full Text] [Related]
8. Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3. Deokar H; Deokar M; Buolamwini JK Mol Divers; 2024 Apr; 28(2):497-507. PubMed ID: 36648693 [TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517 [TBL] [Abstract][Full Text] [Related]
11. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors. Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Dymock BW; See CS Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405 [TBL] [Abstract][Full Text] [Related]
15. In silico identification of natural product inhibitors of JAK2. Zhong HJ; Lin S; Tam IL; Lu L; Chan DS; Ma DL; Leung CH Methods; 2015 Jan; 71():21-5. PubMed ID: 25038528 [TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660 [TBL] [Abstract][Full Text] [Related]
17. Jak2 inhibitor--a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors. Singh KhD; Naveena Q; Karthikeyan M Mol Biosyst; 2014 Aug; 10(8):2146-59. PubMed ID: 24874539 [TBL] [Abstract][Full Text] [Related]
18. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096 [TBL] [Abstract][Full Text] [Related]